Fluor Corporation Common Stock vs Inovio Pharmaceuticals Inc — how do they compare? Fluor Corporation Common Stock trades at $50.68 (market cap $6.82B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Fluor Corporation Common Stock is far larger — about 60.8× Inovio Pharmaceuticals Inc's market cap, and Fluor Corporation Common Stock is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fluor Corporation Common Stock for 1 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| FLR | INO | |
|---|---|---|
Market Cap | $6.82B | $112.19M |
Volume | 1,748,454 | 3,201,278 |
Sector | Industrials | Health |
52-Week High | $57.50 | $2.65 |
52-Week Low | $39.63 | $0.66 |
Typical Hold Time | 1 Days | 43 Days |
Enterprise Value | $4.85B | $83.51M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Fluor provides engineering, procurement, construction, and maintenance services. It works across energy, infrastructure, mining, advanced technology, manufacturing, life sciences, and government projects.
Read more on FLR →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →